Revytal Retatrutide UK: What Is It, How Does It Work, and Where to Get It

This article covers Revytal retatrutide for laboratory research purposes only. Not for human use.

If you’ve been searching for Revytal in the UK, you’ve probably already gone down the rabbit hole a bit. Triple agonist, GLP-1, GIP, glucagon receptor — it sounds like a lot. But once you understand what makes retatrutide different from the other peptides in this class, it actually makes a lot of sense why it’s getting so much attention right now.

This guide covers everything: what Revytal actually is, how the mechanism works, how it compares to tirzepatide and semaglutide, and why the 30MG vial is usually the better research choice over the 10MG.

So What Actually Is Revytal?

Revytal is Arma Peptides’ branded name for retatrutide 30MG. That’s it. The molecule is retatrutide — same compound that Eli Lilly ran through Phase 2 trials and published in the NEJM in 2023. Arma Peptides supply it as a lyophilised research vial at 30MG, with a third-party HPLC Certificate of Analysis confirming ≥99% purity.

The Revytal name exists within Arma Peptides’ product range to mark it as their verified, higher-dose retatrutide SKU. It’s not a different compound. It’s not a proprietary formula. It’s retatrutide, done properly, with the documentation to back it up.

Quick note on the spelling: if you’ve been searching “revital retatrutide” — that’s just a common misspelling you’ll find all over forums and Reddit threads. Same product, same thing, you’re in the right place.

Why Triple Agonist? Why Does It Matter?

Most people who find Revytal have already looked at semaglutide and tirzepatide. So the obvious question is: what does adding the glucagon receptor actually do?

Here’s the quick breakdown of what each receptor brings to the table:

Semaglutide only hits GLP-1. Tirzepatide adds GIP on top. Retatrutide adds the glucagon receptor as well — which is why the Phase 2 data looked so much more significant than anything before it at comparable timepoints.

The glucagon receptor piece is genuinely interesting from a research perspective. It introduces hepatic glucose regulation and energy expenditure as active variables — which neither GLP-1 nor GIP agonism alone can produce. If your research is specifically looking at energy balance, liver fat, or thermogenesis pathways, that third receptor is the reason retatrutide belongs in your protocol where tirzepatide doesn’t.

What Did the Phase 2 Trial Actually Show?

The NEJM paper from June 2023 (Eli Lilly) was a 24-week randomised controlled trial — 338 participants with obesity. The headline number everyone quotes is the 17.5% mean body weight reduction in the highest dose arm (12mg) at 24 weeks.

For context: semaglutide at 68 weeks in STEP-1 hit 14.9%. Retatrutide hit 17.5% at 24 weeks. That’s not nothing.

Beyond body weight, the trial showed dose-dependent improvements in fasting insulin, HbA1c, and triglycerides across all active dosing groups. The tolerability profile was consistent with what you’d expect from a GLP-class compound — mostly GI effects, mostly transient, dose-dependent.

Phase 3 trials are currently underway. The Phase 2 data is what’s driving the current surge in research interest — and why Revytal retatrutide has become one of the most requested compounds in the UK research space through 2025 and into 2026.

Full data: Retatrutide Phase 2 trial — NEJM 2023.

What About the Revytal Pen?

“Revytal pen” gets searched a lot. To be clear: Arma Peptides do not supply a pen device. Revytal comes as a lyophilised powder vial — you reconstitute it with bacteriostatic water and use insulin syringes for administration in your research setup.

The pen format is a clinical delivery thing — Mounjaro pens, Ozempic pens — that’s for prescribed patient use. In a research context, the vial format is standard. It gives you more control over concentration and dosing, which is exactly what you want in a lab setting.

Standard Reconstitution Setup

• Bacteriostatic water for injection (sterile, 0.9% benzyl alcohol)
• Add slowly down the vial wall — don’t inject directly onto the powder
• Swirl gently. Do not shake or vortex — you’ll get aggregation
• U-100 insulin syringes for micro-dosing accuracy
• Refrigerate post-reconstitution at 2–8°C, use within 14–28 days

30MG vs 10MG — Which Should You Get?

Arma Peptides stock both formats. Here’s the honest answer on which to go for:

Every time you reconstitute a peptide you introduce a small stability risk. Fewer reconstitutions over the course of a long study means better peptide integrity throughout. That’s the practical reason the 30MG vial wins for extended research — it’s not just about cost per mg.

Revytal vs Zonjero: Retatrutide vs Tirzepatide

This comes up a lot. Both are GLP-class dual/triple agonists available at the same price point from Arma Peptides. Here’s how to think about which one belongs in your research:

If you want the compound with the most published Phase 3 clinical reference data, Zonjero/tirzepatide wins. If you’re specifically researching the glucagon receptor or want to run a protocol that goes beyond what GLP-1 + GIP can do, Revytal is the one.

Full breakdown: Semaglutide vs Tirzepatide vs Retatrutide — UK Research Comparison 2026.

Storage — Don’t Get This Wrong

Retatrutide is sensitive to heat, light, and moisture. If you’re ordering Revytal, here’s what you need to know:

Before Reconstitution (Lyophilised Powder)

• Short term (up to 6 months): 2–8°C fridge, out of direct light
• Long term (6–18 months): -20°C freezer, sealed, with desiccant
• Let it reach room temp before opening — prevents moisture condensation on the powder

After Reconstitution (Solution)

• Fridge at 2–8°C — do not freeze the solution
• Use within 14–28 days
• Discard if it goes cloudy or particulate — don’t use it
• Always label with the reconstitution date and concentration

Any questions on protocol or storage, Arma Peptides’ team is reachable directly via the contact page.

Is It Legal to Buy Revytal in the UK?

Yes. Retatrutide isn’t a controlled substance in the UK. It isn’t licensed as a medicine either — so it falls into the research chemical category, which means it’s legal to buy and possess for laboratory research purposes.

Arma Peptides supply it under those regulations. The labelling is clear: research use only, not for human or veterinary use. You confirm research intent at checkout. That’s the framework it operates in.

Every vial comes with a third-party Certificate of Analysis — independently verified HPLC purity data, not self-certified. That matters if your lab keeps procurement records or you’re writing a methodology section.

Where to Buy Revytal Retatrutide in the UK

Arma Peptides are one of the only UK-based suppliers doing retatrutide in the 30MG format with a proper independent CoA. Not self-certified, not forwarded from overseas — third-party HPLC verified, dispatched from the UK.

• ≥99% purity — HPLC + mass spec verified
• Independent third-party CoA with every order
• Free UK delivery on orders over £200
• Crypto, bank transfer, credit/debit card
• Discreet packaging, fast dispatch

For the full range of GLP-class research peptides — including semaglutide, tirzepatide, MOTS-c — see the research peptides catalogue.

Quick FAQ

What is Revytal?

Revytal is Arma Peptides’ branded retatrutide 30MG research vial. Retatrutide is a triple GLP-1/GIP/glucagon receptor agonist peptide — the most receptor-complex GLP-class compound currently available for research in the UK. It’s supplied as a lyophilised powder with third-party CoA verification.

Is Revytal the same as Retatrutide?

Yes. Revytal is the product name Arma Peptides use for their retatrutide 30MG vial. Same molecule. The brand name just signals a specific purity standard and documentation setup within their range.

What’s “revital retatrutide”?

Just a spelling variant — you see “revital” instead of “revytal” all over forums and Reddit. It’s the same product. If you were searching for “revital retatrutide UK” you’ve ended up in the right place.

Does Revytal come as a pen?

No. It’s a lyophilised powder vial. Pen devices are for clinical use. In research settings you reconstitute the powder with bacteriostatic water and use insulin syringes — that’s the standard format for lab work.

How does Revytal compare to Zonjero (tirzepatide)?

Retatrutide hits three receptors (GLP-1, GIP, GCGR). Tirzepatide hits two (GLP-1, GIP). The glucagon receptor is the difference — it adds energy expenditure and hepatic metabolism as research variables. If those aren’t in your protocol, tirzepatide is a perfectly good choice. If they are, retatrutide is the one you want.

Is it legal to buy Revytal in the UK?

Yes. It’s a research chemical, not a controlled substance or licensed medicine. Legal to purchase for laboratory research purposes in the UK. Arma Peptides supply it under those regulations.